| An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. |
117 |
| Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3] |
42 |
| Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review |
27 |
| PROMIS (R) Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains |
26 |
| An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2] |
24 |
| Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach |
23 |
| Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol |
23 |
| Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA |
22 |
| A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7] |
20 |
| Methods for Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group |
19 |
| Adjusting for Inflation and Currency Changes Within Health Economic Studies |
16 |
| United States Valuation of EQ-5D-5L Health States Using an International Protocol |
16 |
| Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies |
15 |
| Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge |
15 |
| Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report |
14 |
| Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop |
14 |
| Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease |
14 |
| Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group |
14 |
| Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions |
14 |
| Assessing Rationality in Discrete Choice Experiments in Health: An Investigation into the Use of Dominance Tests |
14 |
| What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life? |
13 |
| Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies? |
13 |
| Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward |
13 |
| A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016) |
12 |
| EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set |
12 |
| Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey |
12 |
| EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. |
12 |
| Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions |
11 |
| Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. |
11 |
| Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom |
11 |
| Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium |
11 |
| The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments |
11 |
| Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers |
11 |
| Patient Access to Medicines for Rare Diseases in European Countries |
10 |
| Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2 |
10 |
| Machine Learning for Health Services Researchers |
10 |
| Mothers' Preferences and Willingness to Pay for Human Papillomavirus Vaccination for Their Daughters: A Discrete Choice Experiment in Hong Kong |
9 |
| Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration |
9 |
| The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value |
9 |
| Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey |
9 |
| A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses |
9 |
| Informing a priori Sample Size Estimation in Qualitative Concept Elicitation Interview Studies for Clinical Outcome Assessment Instrument Development |
9 |
| Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective |
9 |
| The Problem of Rarity: Estimation of Prevalence in Rare Disease |
9 |
| Bayesian Networks for Risk Prediction Using Real-World Data: A Tool for Precision Medicine |
9 |
| Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies |
9 |
| Alternative Weighting Approaches for Anchored Matching-Adjusted Indirect Comparisons via a Common Comparator |
8 |
| Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models |
8 |
| Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L |
8 |
| Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D? |
8 |
